Communiqués Mesoblast Limited Nasdaq

Actions

MESO

US5907174016

Temps réel estimé Cboe BZX Autres places de cotation 18:49:40 08/07/2024			Varia. 5j.	Varia. 1 janv.
7,79 ^USD	+0,65 %		+12,68 %	+247,27 %

02/07	Mesoblast va déposer une demande de licence biologique auprès de la FDA américaine pour une thérapie cellulaire	MT
01/07	Mesoblast va déposer une demande de licence biologique pour Ryoncil	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

MESOBLAST TO FILE BIOLOGIC LICENSE APPLICATION FOR RYONCIL FDA APPROVAL NEXT WEEK	02/07	AQ
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week	01/07	AQ
Mesoblast Corporate Presentation at Investor Conference	03/06	AQ
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	30/04	AQ
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK	28/03	AQ
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	26/03	AQ
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	14/03	AQ
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	11/03	AQ
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	28/02	AQ
Mesoblast Financial Results and Corporate Update Webcast	26/02	AQ
MESOBLAST - UNITED STATES FOOD & DRUG ADMINISTRATION GRANTS MESOBLAST ORPHAN-DRUG DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	15/02	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	15/02	AQ
MESOBLAST LIMITED - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2023	31/01	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	31/01	AQ
MESOBLAST - UNITED STATES FOOD AND DRUG ADMINISTRATION GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	19/01	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	19/01	AQ
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease	27/11	AQ
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD	22/11	AQ
MESOBLAST - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2023	31/10/23	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023	31/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Mesoblast Limited Nasdaq

Actions

MESO

US5907174016

Communiqués

Filtres